Preserving Competition, FTC Requires Divestitures Before Allowing Teva�s $7.4 Billion Acquisition of IVAX: "Under a consent agreement announced today, the Federal Trade Commission will allow Teva Pharmaceutical Industries Ltd.'s (Teva) proposed acquisition of IVAX Corporation (IVAX), provided the companies sell the rights and assets needed to manufacture and/or market 15 generic pharmaceutical products"
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment